Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001211765 | SCV001383320 | pathogenic | Hereditary spastic paraplegia 47 | 2019-06-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys298*) in the AP4B1 gene. It is expected to result in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in AP4B1 are known to be pathogenic (PMID: 22290197, 24700674, 24781758). This variant has not been reported in the literature in individuals with AP4B1-related conditions. This variant is present in population databases (rs746462207, ExAC 0.006%). |
Gene |
RCV003127686 | SCV003803280 | pathogenic | not provided | 2025-04-16 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001211765 | SCV004021055 | pathogenic | Hereditary spastic paraplegia 47 | 2023-06-12 | criteria provided, single submitter | clinical testing | Variant summary: AP4B1 c.894T>A (p.Cys298X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 2.4e-05 in 251476 control chromosomes. To our knowledge, no occurrence of c.894T>A in individuals affected with Spastic Paraplegia 47, Autosomal Recessive and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 . All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Genome- |
RCV001211765 | SCV004050676 | pathogenic | Hereditary spastic paraplegia 47 | 2023-04-11 | criteria provided, single submitter | clinical testing |